

## Retraction: High-Avidity T Cells Are Preferentially Tolerized in the Tumor Microenvironment

The editors and authors retract the article titled "High-Avidity T Cells Are Preferentially Tolerized in the Tumor Microenvironment," which was published in the January 15, 2013 issue of *Cancer Research* (1), based on the findings of data falsification regarding Fig. 5A. Following review by an NIH investigation committee, NIH found the author Stephanie Watkins was the sole individual responsible for the instances of research misconduct. None of the other authors were aware of the misconduct.

Six of the seven authors have agreed to this retraction and they are as follows:

Ziqiang Zhu

Tumor Immunity and Tolerance Section, Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland

Vinod Singh

Tumor Immunity and Tolerance Section, Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland

Vincenzo Bronte

Department of Pathology, University of Verona, Verona, Italy

Jennifer L. Shoe

Laboratory Animal Sciences Program, SAIC-Frederick, NCI, Frederick, Maryland

Lionel Feigenbaum

Laboratory Animal Sciences Program, SAIC-Frederick, NCI, Frederick, Maryland

Arthur A. Hurwitz

Tumor Immunity and Tolerance Section, Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland

### Reference

1. Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, et al. High-avidity T cells are preferentially tolerized in the tumor microenvironment. *Cancer Res* 2013;73:595–604.

Published OnlineFirst March 24, 2016.

doi: 10.1158/0008-5472.CAN-16-0506

©2016 American Association for Cancer Research.